Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease

Movement Disorders

Volumn 15, Issue 3, 2000, Pages 552-560

  Aylward, Elizabeth H ^a,b,d   Codori, Ann Marie ^c   Rosenblatt, Adam ^a   Sherr, Meeia ^a   Brandt, Jason ^c   Stine, Oscar C ^a   Barta, Patrick E ^a   Pearlson, Godfrey D ^a   Ross, Christopher A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Division of Medical Psychology   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Caudate; Hungtington's disease; Longitudinal change; MRI; Presymptomatic

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; STAGING; SYMPTOM;

ADULT; AGED; ATROPHY; CAUDATE NUCLEUS; FEMALE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION;

EID: 0034087487     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P     Document Type: Article

References (38)

1. Ross CA, Margolis RL, Rosenblatt A, Ranen NG, Becher MW, Aylward E. Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA) (Reviews in Molecular Medicine). Medicine 1997;76:305-338.
2. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
3. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
4. Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992;31:69-75.
5. Jernigan TL, Salmon DP, Butters N, Hesselilnk J. Cerebral structure on MRI. Part II: specific changes in Alzheimer's and Huntington's diseases. Biol Psychiatry 1991;29:68-81.
6. Young AB, Penney JB, Sarosta-Rubinstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986;20:296-303.
7. Mazziotta JC, Phelps ME. Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;12:357-362.
8. Hayden MR, Martin WR, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986;36:888-894.
9. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119: 2085-2095.
10. 11C] Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998;43:253-255.
11. Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WR. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology 1987;37:1441-1447.
12. Aylward EH, Brandt J, Codori A, Mangus R, Barta P, Harris G. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994; 44:823-828.
13. Aylward E, Codori A, Barta P, Pearlson GP, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington's disease. Arch Neurol 1996;53:1293-1296.
14. Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology 1992;34:487-489.
15. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 1997;48:394-399.
16. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
17. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's Disease Rating Scale: a follow up. Mov Disord 1998;13:915-919.
18. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995;10:211-214.
19. Shoulson I, Fahn S. Huntington's disease: clinical care and evaluation. Neurology 1979;29:1-3.
20. Penney JB, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
21. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehavioral Toxicology and Teratology 1983;5:605-609.
22. Brandt J, Bylsma FW, Gross R, et al. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996; 46:527-531.
23. Giordani B, Berent S, Boivin MJ, et al. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol 1995;52:59-64.
24. Campodonico JR, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. J Neurol Neurosurg Psychiatry 1996;61:621-624.
25. Rubin AJ, King WM, Reinbold KA, Shoulson I. Quantitative Iongitudinal assessment of saccades in Huntington's disease. Journal of Clinical Neuro-opthalmology 1993;13:59-66.
26. Ehle AL, Stewart RM, Lellelid NA, Leventhal NA. Evoked potentials in Huntington's disease: a comparative and longitudinal study. Arch Neurol 1984;41:379-382.
27. The Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology 1998;50:1366-1373.
28. Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 1998;282:1072-1074.
29. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 1989;25:252-259.
30. Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996;3:321-323.
31. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 1995;45:1867-1873.
32. Folstein SE, Leigh RR, Parhad IM, Folstein MF. The diagnosis of Huntington's disease. Neurology 1986;36:1279-1283.
33. Stine OC, Pleasant N, Franz ML, Abbot MH, Folstein SE, Ross CA. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 1993; 2:1547-1549.
34. Grafton ST, Mazziotta JC, Pahl JJ, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol 1992;49:1161-1167.
35. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996;119: 2085-2095.
36. Hussey D, Stewart D, Houle S, Guttman M. [C-11] raclopride striatal binding potential as a measure of Huntington's disease progression: implications for prospective neuroprotective studies [Abstract]. J Nucl Med 1998;39:209P.
37. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
38. Rosenblatt A, Margolis RL, Becher MW, et al. Does CAG repeat number predict the rate of pathological changes in Huntington's disease? Ann Neurol 1998;44:708-709.